keyword
MENU ▼
Read by QxMD icon Read
search

naltrexon

keyword
https://www.readbyqxmd.com/read/29678127/a-health-economic-model-to-assess-the-cost-effectiveness-of-optifast-%C3%A2-for-the-treatment-of-obesity-in-usa
#1
Mark Nuijten, Agnieszka Marczewska, Krysmaru Araujo Torress, Bahareh Rasouli, Moreno Perugini
OBJECTIVES: Obesity is associated with high direct medical costs and indirect costs resulting from productivity loss. High prevalence of obesity generates a justified need to identify cost-effective weight loss approaches from a payer's perspective. Within the variety of weight management techniques, OPTIFAST® is a clinically recognized and scientifically proven total meal replacement Low Calorie Diet that provides meaningful results in terms of weight loss and reduction in comorbidities...
April 20, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29677019/mu-opioid-receptors-in-nociceptive-afferents-produce-a-sustained-suppression-of-hyperalgesia-in-chronic-pain
#2
Amie Severino, Wenling Chen, Joshua K Hakimian, Brigitte L Kieffer, Claire Gaveriaux-Ruff, Wendy Walwyn, Juan Carlos Marvizon
The latent sensitization model of chronic pain reveals that recovery from some types of long-term hyperalgesia is an altered state in which nociceptive sensitization persists but is suppressed by the ongoing activity of analgesic receptors such as µ-opioid receptors (MORs). To determine whether these MORs are the ones present in nociceptive afferents, we bred mice expressing Cre-recombinase under the Nav1.8 channel promoter (Nav1.8cre) with MOR-floxed mice (flMOR). These Nav1.8cre/flMOR mice had reduced MOR expression in primary afferents, as revealed by quantitative PCR, in situ hybridization and immunofluorescence colocalization with the neuropeptide CGRP...
April 17, 2018: Pain
https://www.readbyqxmd.com/read/29674251/outpatient-transition-to-extended-release-injectable-naltrexone-for-patients-with-opioid-use-disorder-a-phase-3-randomized-trial
#3
Adam Bisaga, Paolo Mannelli, Miao Yu, Narinder Nangia, Christine E Graham, D Andrew Tompkins, Thomas R Kosten, Sarah C Akerman, Bernard L Silverman, Maria A Sullivan
BACKGROUND: Injectable extended-release naltrexone (XR-NTX), approved to prevent relapse to opioid dependence, requires initial abstinence. This multisite outpatient clinical trial examined the efficacy and safety of low-dose oral naltrexone (NTX), combined with a brief buprenorphine (BUP) taper and standing ancillary medications, for detoxification and induction onto XR-NTX. METHODS: Patients (N = 378) were randomized, stratified by primary short-acting opioid-of-use, to one of three regimens: NTX + BUP; NTX + placebo BUP (PBO-B); placebo NTX (PBO-N) + PBO-B...
April 10, 2018: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/29670752/quality-of-life-binge-eating-and-sexual-function-in-participants-treated-for-obesity-with-sustained-release-naltrexone-bupropion
#4
A Halseth, K Shan, K Gilder, M Malone, L Acevedo, K Fujioka
Objective: This multicenter, randomized, controlled, open-label trial examined weight-related quality of life, control over eating behaviour and sexual function after 26 weeks of treatment with either 32 mg naltrexone sustained release (SR)/360 mg bupropion SR plus a comprehensive lifestyle intervention program (NB + CLI, N = 153) or usual care (UC, N = 89), which included minimal lifestyle intervention. Methods: Impact of Weight on Quality of Life-Lite, Binge Eating Scale and Arizona Sexual Experiences Scale were assessed at baseline (BL) and weeks 16 and 26...
April 2018: Obesity Science & Practice
https://www.readbyqxmd.com/read/29668645/coverage-of-medications-that-treat-opioid-use-disorder-and-opioids-for-pain-management-in-marketplace-plans-2017
#5
Haiden A Huskamp, Lauren E Riedel, Colleen L Barry, Alisa B Busch
BACKGROUND: Efficacious medications to treat opioid use disorders (OUDs) have been slow to diffuse into practice, and insurance coverage limits may be one important barrier. OBJECTIVES: To compare coverage for medications used to treat OUDs and opioids commonly prescribed for pain management in plans offered on the 2017 Health Insurance Marketplace exchanges. RESEARCH DESIGN: We identified a sample of 100 plans offered in urban and in rural counties on the 2017 Marketplaces, weighting by population...
April 17, 2018: Medical Care
https://www.readbyqxmd.com/read/29658501/-anhedonia-depression-anxiety-and-craving-in-opioid-dependent-patients-stabilized-on-oral-naltrexone-or-naltrexone-implant
#6
E M Krupitsky, E E Zvartau, E A Blokhina, E V Verbitskaya, V Yu Wahlgren, M V Tsoy-Podosenin, N M Bushara, A M Burakov, D V Masalov, T N Romanova, A A Tiurina, V Ya Palatkin, T S Yaroslavtseva, G Yu Sulimov, A Pecoraro, G Woody
AIM: To assess the relationship between long-term naltrexone treatment and anxiety, depression and craving in opioid dependent individuals. MATERIAL AND METHODS: Opioid dependent patients (n=306) were enrolled in a three cell (102ss/cell) randomized, double blind, double dummy, placebo-controlled 6-month trial comparing extended release implantable naltrexone with oral naltrexone and placebo (oral and implant). Monthly assessments of affective responses used a Visual Analog Scale for opioid craving, the Beck Depression Inventory, Spielberger Anxiety Inventory, and the Ferguson and Chapman Anhedonia Scales...
2018: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/29658443/evaluation-of-the-effect-of-uremic-serum-on-hepatic-reductase-functional-expression
#7
Osama Y Alshogran, Esra A F Al-Obaidi, Belal A Al-Husein, Ashraf O Oweis
BACKGROUND: The nonrenal clearance of drugs mediated by hepatic reduction is selectively altered by kidney disease. This study evaluated the influence of uremic serum on the expression and activity of reductase enzymes. METHODS: Human hepatocellular carcinoma cells (HepG2) were incubated with 5% pooled serum collected from patients with hemodialysis (pre- and post-dialysis session) or control subjects. The mRNA expression of various aldo-keto (AKR1C) and carbonyl (CBR) reductases were measured...
April 16, 2018: Drug Metabolism Letters
https://www.readbyqxmd.com/read/29651781/abuse-deterrent-opioid-formulations-a-key-ingredient-in-the-recipe-to-prevent-opioid-disasters
#8
Aaron J Salwan, Nicholas E Hagemeier, Sam Harirforoosh
The US Food and Drug Administration (FDA) is encouraging the innovation of long-acting opioid formulations that are manipulation-resistant. The purpose of this commentary is to assess the benefits and limitations of abuse-deterrent opioid formulations (ADFs) and discuss their role in mitigating the current opioid epidemic. ADFs have been created with chemical properties that make it difficult for people who non-medically use prescription drugs to crush and dissolve opioid tablets, as well as by combining opioids with antagonists such as naloxone or naltrexone, which are released only when the dosage form has been manipulated or the drug is taken by a non-intended route...
April 12, 2018: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29626646/cirrhosis-induced-by-bile-duct-ligation-alleviates-acetic-acid-intestinal-damages-in-rats-involvements-of-nitrergic-and-opioidergic-systems
#9
Nastaran Rahimi, Mahsa Hassanipour, Narges Sistany Allahabadi, Fatemeh Sabbaghziarani, Maryam Yazdanparast, Ahmadreza Dehpour
BACKGROUND: Colitis, a colonic inflammatory condition, showed a linkage with hepatobiliary disorders such as cirrhosis. It has been reported that both endogenous opioids and nitric oxide (NO) play critical roles in colitis pathogenesis. Moreover, opioid and NO levels showed elevation in patients with cirrhosis. The aim of this study was to evaluate the effect of cirrhosis on the experimental model of colitis and the possible involvement of opioidergic/nitrergic systems in rats. METHODS: Colitis was induced by acetic acid 28 days after bile duct ligation (BDL)...
November 22, 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/29617066/the-mixed-opioid-receptor-antagonist-naltrexone-mitigates-stimulant-induced-euphoria-a-double-blind-placebo-controlled-trial-of-naltrexone
#10
Thomas J Spencer, Pradeep Bhide, Jinmin Zhu, Stephen V Faraone, Maura Fitzgerald, Amy M Yule, Mai Uchida, Andrea E Spencer, Anna M Hall, Ariana J Koster, Leah Feinberg, Sarah Kassabian, Barbara Storch, Joseph Biederman
OBJECTIVE: Supratherapeutic doses of methylphenidate activate μ-opioid receptors, which are linked to euphoria. This study assessed whether naltrexone, a mixed μ-opioid antagonist, may attenuate the euphoric effects of stimulants, thereby minimizing their abuse potential in subjects with attention-deficit/hyperactivity disorder (ADHD). METHODS: We conducted a 6-week, double-blind, placebo-controlled, randomized clinical trial of naltrexone in adults with DSM-IV ADHD receiving open treatment with a long-acting formulation of methylphenidate (January 2013 to June 2015)...
March 13, 2018: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29616881/the-use-of-ketamine-xylazine-or-butorphanol-azaperone-medetomidine-to-immobilize-american-black-bears-ursus-americanus
#11
Ryan H Williamson, Lisa L Muller, Coy Blair
  Wildlife anesthetic protocols must offer rapid inductions and recoveries, be physiologically safe, and be minimally regulated. With this in mind, we evaluated differences in induction and recovery times and physiological parameters in 33 American black bears ( Ursus americanus) anesthetized with ketamine-xylazine (KX) or immobilized with a commercial drug combination of butorphanol, azaperone, and medetomidine (BAM). Dose was based on mass estimated from field observations. Bears were housed at Appalachian Bear Rescue, Townsend, Tennessee, US, or free-ranging within the Great Smoky Mountains National Park (Tennessee and North Carolina, US) and chemically immobilized for management purposes...
April 4, 2018: Journal of Wildlife Diseases
https://www.readbyqxmd.com/read/29607497/low-dose-naltrexone-for-induction-of-remission-in-crohn-s-disease
#12
REVIEW
Claire E Parker, Tran M Nguyen, Dan Segal, John K MacDonald, Nilesh Chande
BACKGROUND: Crohn's disease is a transmural, relapsing inflammatory condition afflicting the digestive tract. Opioid signalling, long known to affect secretion and motility in the gut, has been implicated in the inflammatory cascade of Crohn's disease. Low dose naltrexone, an opioid antagonist, has garnered interest as a potential therapy. OBJECTIVES: The primary objective was to evaluate the efficacy and safety of low dose naltrexone for induction of remission in Crohn's disease...
April 1, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29605483/severe-opioid-withdrawal-precipitated-by-vivitrol%C3%A2
#13
R S Wightman, L S Nelson, J D Lee, L M Fox, S W Smith
The risk of severe precipitated opioid withdrawal (POW) is amplified when precipitated by a long-acting opioid antagonist. IM extended release naltrexone (XRNTX;Vivitrol®) is an FDA approved therapy to prevent relapse of opioid and alcohol abuse. Two cases of precipitated opioid withdrawal from XRNTX are presented that illustrate different patient reactions to POW. A 56-year-old woman developed a hypertensive emergency and required continuous intravenous vasodilator, clonidine, and intensive care monitoring after re-initiation of XRNTX following opioid relapse...
March 21, 2018: American Journal of Emergency Medicine
https://www.readbyqxmd.com/read/29602178/ethanol-exposure-history-and-alcoholic-reward-differentially-alter-dopamine-release-in-the-nucleus-accumbens-to-a-reward-predictive-cue
#14
Amanda M Fiorenza, Tatiana A Shnitko, Kaitlin M Sullivan, Sudheer R Vemuru, Alexander Gomez-A, Julie Y Esaki, Charlotte A Boettiger, Claudio Da Cunha, Donita L Robinson
BACKGROUND: Conditioned stimuli (CS) that predict reward delivery acquire the ability to induce phasic dopamine release in the nucleus accumbens. This dopamine release may facilitate conditioned approach behavior, which often manifests as approach to the site of reward delivery (called 'goal-tracking') or to the CS itself (called 'sign-tracking'). Previous research has linked sign-tracking in particular to impulsivity and drug self-administration, and addictive drugs may promote the expression of sign-tracking...
March 30, 2018: Alcoholism, Clinical and Experimental Research
https://www.readbyqxmd.com/read/29596725/antagonists-in-the-medical-management-of-opioid-use-disorders-historical-and-existing-treatment-strategies
#15
REVIEW
Adam Bisaga, Paolo Mannelli, Maria A Sullivan, Suzanne K Vosburg, Peggy Compton, George E Woody, Thomas R Kosten
BACKGROUND AND OBJECTIVES: Opioid use disorder (OUD) is a chronic condition with potentially severe health and social consequences. Many who develop moderate to severe OUD will repeatedly seek treatment or interact with medical care via emergency department visits or hospitalizations. Thus, there is an urgent need to develop feasible and effective approaches to help persons with OUD achieve and maintain abstinence from opioids. Treatment that includes one of the three FDA-approved medications is an evidence-based strategy to manage OUD...
April 2018: American Journal on Addictions
https://www.readbyqxmd.com/read/29595375/medications-for-opioid-use-disorder-in-the-department-of-veterans-affairs-va-health-care-system-historical-perspective-lessons-learned-and-next-steps
#16
Jessica J Wyse, Adam J Gordon, Steven K Dobscha, Benjamin J Morasco, Elizabeth Tiffany, Karen Drexler, Friedhelm Sandbrink, Travis I Lovejoy
The US Department of Veterans Affairs (VA), the largest health care system in the US, has been confronted with the health care consequences of opioid disorder (OUD). Increasing access to quality OUD treatment, including pharmacotherapy, is a priority for the VA. We examine the history of medications (e.g., methadone, buprenorphine, injectable naltrexone) used in the treatment of OUD within VA, document early and ongoing efforts to increase access and build capacity, primarily through the use of buprenorphine, and summarize research examining barriers and facilitators to prescribing and medication receipt...
March 29, 2018: Substance Abuse
https://www.readbyqxmd.com/read/29593789/drugs-involved-in-dyslipidemia-and-obesity-treatment-focus-on-adipose-tissue
#17
REVIEW
Sofia Dias, Sílvia Paredes, Laura Ribeiro
Metabolic syndrome can be defined as a state of disturbed metabolic homeostasis characterized by visceral obesity, atherogenic dyslipidemia, arterial hypertension, and insulin resistance. The growing prevalence of metabolic syndrome will certainly contribute to the burden of cardiovascular disease. Obesity and dyslipidemia are main features of metabolic syndrome, and both can present with adipose tissue dysfunction, involved in the pathogenic mechanisms underlying this syndrome. We revised the effects, and underlying mechanisms, of the current approved drugs for dyslipidemia and obesity (fibrates, statins, niacin, resins, ezetimibe, and orlistat; sibutramine; and diethylpropion, phentermine/topiramate, bupropion and naltrexone, and liraglutide) on adipose tissue...
2018: International Journal of Endocrinology
https://www.readbyqxmd.com/read/29593550/naltrexone-reverses-ethanol-preference-and-protein-kinase-c-activation-in-drosophila-melanogaster
#18
Rajeswari Koyyada, Nilesh Latchooman, Julius Jonaitis, Samir S Ayoub, Olivia Corcoran, Stefano O Casalotti
Alcohol use disorder (AUD) is a major health, social and economic problem for which there are few effective treatments. The opiate antagonist naltrexone is currently prescribed clinically with mixed success. We have used naltrexone in an established behavioral assay (CAFE) in Drosophila melanogaster that measures the flies' preference for ethanol-containing food. We have confirmed that Drosophila exposed to ethanol develop a preference toward this drug and we demonstrate that naltrexone, in a dose dependant manner, reverses the ethanol-induced ethanol preference...
2018: Frontiers in Physiology
https://www.readbyqxmd.com/read/29590436/testing-mediators-of-reduced-drinking-for-veterans-in-alcohol-care-management
#19
Dezarie Moskal, Stephen A Maisto, Kyle Possemato, Kevin G Lynch, David W Oslin
Introduction: Alcohol Care Management (ACM) is a manualized treatment provided by behavioral health providers working in a primary care team aimed at increasing patients' treatment engagement and decreasing their alcohol use. Research has shown that ACM is effective in reducing alcohol consumption; however, the mechanisms of ACM are unknown. Therefore, the purpose of this study is to examine the mechanisms of change in ACM in the context of a randomized clinical trial evaluating the effectiveness of ACM...
March 26, 2018: Military Medicine
https://www.readbyqxmd.com/read/29565661/impact-of-medicaid-expansion-on-access-to-opioid-analgesic-medications-and-medication-assisted-treatment
#20
Alana Sharp, Austin Jones, Jennifer Sherwood, Oksana Kutsa, Brian Honermann, Gregorio Millett
OBJECTIVES: To assess the impact of the expansion of Medicaid eligibility in the United States on the opioid epidemic, as measured through increased access to opioid analgesic medications and medication-assisted treatment. METHODS: Using Medicaid enrollment and reimbursement data from 2011 to 2016 in all states, we evaluated prescribing patterns of opioids and the 3 Food and Drug Administration-approved medications used in treating opioid use disorders by using 2 statistical models...
March 22, 2018: American Journal of Public Health
keyword
keyword
88617
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"